Though the baseline illness severity was uneven, with more severe patients in the itolizumab arm, the medication showed great ...

Bengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global ...

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to ...

Ulcerative colitis affects daily life, but proper management can help maintain quality of life. Learn how to cope with this ...

The Crohn’s & Colitis Foundation and the American Gastroenterological Association (AGA) are excited to host the annual Crohn’s & Colitis Congress®, taking place Feb. 6-8, in San Francisco, CA. This ...

Equillium and Biocon announce positive data from phase 2 study of itolizumab to treat moderate to severe ulcerative colitis: Our Bureau, Bengaluru Friday, February 7, 2025, 10:30 ...

Reality star Kwame Appiah is urging his fans to take their health seriously and keep an eye out for unusual symptoms as he reveals his diagnosis. Sharing his own symptoms, the Love is Blind star ...

Janus kinase (JAK) inhibitors can quickly and effectively manage ulcerative colitis (UC), especially when more conventional treatments haven’t worked. UC is a type of inflammatory bowel disease ...

Equillium, Inc. (NASDAQ:EQ), a biotechnology company with a market capitalization of $25.15 million and current stock price of $0.71, announced today the positive outcomes of their Phase 2 clinical ...

Ulcerative colitis (UC) is a long-term condition that causes inflammation and ulcers (sores) in the tissue that lines your rectum and colon—which make up most of your lower intestine.

Proctitis affects the rectum, whereas ulcerative colitis can affect the colon, the rectum, or both parts of the intestine. Ulcerative colitis (UC) is a form of inflammatory bowel disease (IBD ...